How to taper Zoloft (sertraline) and switch to Prozac (fluoxetine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Taper Sertraline (Zoloft) and Switch to Fluoxetine (Prozac)

When switching from sertraline (Zoloft) to fluoxetine (Prozac), implement a gradual tapering schedule of sertraline with dose reductions of approximately 25% of the most recent dose every 1-2 weeks, followed by initiation of fluoxetine at a low dose after sertraline is completely discontinued or at a very low dose. 1

Sertraline Tapering Process

  • Begin by reducing sertraline by 25% of the current dose every 1-2 weeks (e.g., from 100 mg to 75 mg, then to 56.25 mg, etc.) 1
  • Monitor closely for withdrawal symptoms which may include anxiety, irritability, insomnia, dizziness, electric shock-like sensations, and gastrointestinal disturbances 2
  • If withdrawal symptoms occur, slow the taper rate or temporarily return to the previous dose until symptoms subside 1
  • For patients on higher doses or who have been on sertraline long-term, an even more gradual taper may be warranted 3
  • Continue tapering until reaching the lowest available dose (typically 25 mg for sertraline) 1
  • For the final reduction from 25 mg to zero, consider alternate-day dosing for 1-2 weeks before complete discontinuation 3

Initiating Fluoxetine

  • Start fluoxetine at a low dose (10 mg every other morning) after sertraline is completely discontinued or at a very low dose 1
  • Fluoxetine's very long half-life makes it less likely to cause withdrawal symptoms when eventually discontinued 1
  • Increase fluoxetine gradually as needed up to 20 mg every morning 1
  • Monitor for side effects which may include activation, nervousness, insomnia, and gastrointestinal disturbances 1

Monitoring During Transition

  • Schedule more frequent follow-up appointments during the tapering and switching period to assess for return of original symptoms and emergence of withdrawal symptoms 4
  • Be aware that withdrawal symptoms may be mistaken for relapse of the underlying condition 3
  • Monitor for potential drug interactions if there is any overlap between sertraline and fluoxetine 2
  • Watch for signs of serotonin syndrome if there is any overlap in dosing (symptoms include mental status changes, autonomic instability, neuromuscular symptoms, and gastrointestinal symptoms) 2

Special Considerations

  • If the patient is also taking benzodiazepines, consider tapering benzodiazepines separately and with greater caution due to higher risks associated with benzodiazepine withdrawal 5
  • Consider adding adjunctive medications temporarily to manage withdrawal symptoms if needed (e.g., trazodone for insomnia) 1
  • Withdrawal symptoms should be preempted and treated with liberal use of adjuvant agents along with adequate clinician support 1
  • Standard tapering schedules of 2-4 weeks may be too rapid for many patients; hyperbolic tapering (smaller reductions as the dose gets lower) may be more effective in reducing withdrawal symptoms 3, 6

Common Pitfalls to Avoid

  • Avoid abrupt discontinuation of sertraline, which can precipitate withdrawal symptoms 2
  • Do not mistake withdrawal symptoms for relapse of the original condition 7
  • Avoid starting fluoxetine at too high a dose, which may increase side effects 1
  • Be cautious about potential drug interactions between sertraline and fluoxetine if there is any overlap in dosing 2
  • Do not rush the tapering process; slower tapering is generally more successful in reducing withdrawal symptoms 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Lamotrigine Tapering Protocol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Benzodiazepine Discontinuation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.